Interactions between RAMP2 and CRF receptors: The effect of receptor subtypes, splice variants and cell context. by Bailey, Sian et al.
 1 
Interactions Between RAMP2 And CRF Receptors: The Effect Of Receptor Subtypes, 
Splice Variants And Cell Context. 
 
Sian Baileya,1, Matthew Harrisb,1, Kerry Barkanb, Ian Winfieldb, Matthew Thomas Harperb, 
John Simmsc,d, Graham Laddsb,Á, Mark Wheatleya,d,e,Á and David Poynerc,Á 
 
aSchool of Biosciences, University of Birmingham, Edgbaston, Birmingham, B15 2TQ, UK 
bDepartment of Pharmacology, University of Cambridge, Cambridge, CB2 1PD, UK 
cLife and Health Sciences, Aston University, Birmingham, B4 7ET, UK  
dSchool of Life Sciences, Coventry University, Coventry, CV1 5FB, UK 
eCentre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and 
University of Nottingham, Midlands, UK. 
 
1 Co-first authors. 
ÁCorresponding authors.   
E-mail addresses: mark.wheatley@coventry.ac.uk (M. Wheatley), grl30@cam.ac.uk (G. 
Ladds), d.r.poyner@aston.ac.uk (D. Poyner). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*REVISED Manuscript (text UNmarked)
Click here to view linked References
 2 
 
ABSTRACT 
 
Corticotrophin releasing factor (CRF) acts via two family B G-protein-coupled receptors, 
CRFR1 and CRFR2.  Additional subtypes exist due to alternative splicing. CRFR1Dis the 
most widely expressed subtype and lacks a 29-residue insert in the first intracellular loop that 
is present in CRFR1E. It has been shown previously that co-expression of CRFR1E with 
receptor activity modifying protein 2 (RAMP2) in HEK 293S cells increased the cell-surface 
expression of both proteins suggesting a physical interaction as seen with RAMPs and 
calcitonin receptor-like receptor (CLR).This study investigated the ability of 
CRFR1DCRFR1E and CRFR2E to promote cell-surface expression of FLAG-tagged 
RAMP2. Four different cell-lines were utilised to investigate the effect of varying cellular 
context; COS-7, HEK 293T, HEK 293S and ['CTR]HEK 293 (which lacks endogenous 
calcitonin receptor). In all cell-lines, CRFR1Dand CRFR1E enhanced RAMP2 cell-surface 
expression. The magnitude of the effect on RAMP2 was dependent on the cell-line 
(['CTR]HEK 293>COS-7>HEK 293T>HEK 293S). RT-PCR indicated this variation may 
relate to differences in endogenous RAMP expression between cell types. Furthermore, pre-
treatment with CRF resulted in a loss of cell-surface FLAG-RAMP2 when it was co-
expressed with CRFR1 subtypes. CRFR2E co-expression had no effect on RAMP2 in any 
cell-line. Molecular modelling suggests that the potential contact interface between the 
extracellular domains of RAMP2 and CRF receptor subtypes is smaller than that of RAMP2 
and CRL, the canonical receptor:RAMP pairing, assuming a physical interaction. 
Furthermore, a specific residue difference between CRFR1 subtypes (glutamate) and 
CRFR2E (histidine) in this interface region may impair CRFR2ERAMP2 interaction by 
electrostatic repulsion.
  
 
Keywords: Receptor activity modifying protein (RAMP), corticotrophin releasing factor 
receptor (CRFR), family B GPCR, splice variants, translocation. 
 
Abbreviations: ACTH, adrenocorticotropic hormone; CGRP, calcitonin gene-related peptide; 
CLR, calcitonin receptor-like receptor; CRF, corticotrophin releasing factor; CRFR, 
corticotrophin releasing factor receptor; ECD, extracellular domain; ELISA, enzyme-linked 
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immunosorbant assay; FACS, fluorescence-activated cell sorting; GPCR, G-protein-coupled 
receptor; HA, haemagglutinin tag; RAMP, receptor activity modifying protein.  
 
 
 
 
 
1. Introduction 
 
Corticotrophin releasing factor (CRF) is produced by the hypothalamus and acts on the 
anterior pituitary to release adrenocorticotropic hormone (ACTH), which in turn releases 
cortisol from the adrenal cortex. CRF also has numerous actions in the central nervous 
system related to stress and anxiety [1]. The hormone acts via two family B G-protein-
coupled receptors (GPCRs), CRFR1 and CRFR2, and there are splice variants of both 
receptors. The CRFR1 is the best characterised, with high expression in the pituitary, adrenal 
gland and various brain regions. Furthermore, it is a target for anxiolytic drugs [1]. The full 
length sequence of the CRFR1 is that of the E-subtype. However, in humans the most widely 
expressed isoform is the D-subtype, which lacks exon 6 and consequentially has a 29-residue 
deletion (residues 146-174) in intracellular loop 1 compared to CRFR1E>@. CRFR1E shows 
weaker coupling to Gs compared to the CRFR1D, typically resulting in >10-fold lower 
potency for CRF [1, 2]. For CRFR2, the E-isoform is the major splice variant as the 
CRFR2Dlacks a signal peptide at its N-terminus, so tends to be retained intracellularly [3].  
 
Many family B GPCRs can form complexes with receptor activity modifying proteins 
(RAMPs). In mammals, RAMPs form a family of three single-pass membrane proteins 
(RAMP1, RAMP2, RAMP3). They have a range of effects on GPCRs including promotion of 
cell-surface expression plus modulation of ligand binding profile and signal transduction 
pathways [4]. The archetypical RAMP:GPCR interaction is that between a RAMP and the 
calcitonin receptor-like receptor (CLR) where there is direct interaction between the two 
proteins [5, 6]. When assaying intracellular cAMP signalling, a calcitonin gene-related 
peptide (CGRP) receptor is created by a RAMP1:CLR complex whereas an adrenomedullin 
receptor is generated by RAMP2:CLR or RAMP3:CLR complexes [7].  
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It has been shown previously that co-expression of RAMP2 with CRFR1E results in 
increased cell-surface expression of both proteins [8]. However, the ability of RAMP2 to 
interact with the more widely expressed CRF receptor, the CRFR1Dsubtype, was not 
investigated. The purpose of the current study was to determine whether CRFR1D or 
CRFR2E could interact (either directly or indirectly) with RAMP2 and change cell-surface 
expression, as previously reported for CRFR1E. In addition, as the magnitude of the effect 
reported previously with RAMP2:CRFR1E complexes was cell-line dependent [8], the 
influence of cell context on RAMP2:CRFR interaction was also investigated. Finally, on the 
assumption of a direct interaction between the CRFR subtypes and RAMP2 (as seen with 
CLR and RAMPs, [5, 6]), molecular modelling was then employed to provide mechanistic 
insights into differences that had been observed experimentally between RAMP2:CRFR1 and 
RAMP2:CRFR2.  
 
 
 
 
2. Materials and methods 
 
2.1. Constructs 
 
Both the D and E variants of haemagglutinin (HA)-tagged CRFR1 were constructed in the 
same way, with the HA-tag being inserted immediately after the signal peptide, between A23 
(the end of the predicted signal peptide) and S24, the start of the mature protein. This 
replicates the construct design used previously [6]. These two constructs were custom-
synthesised by GenScript (New Jersey, U.S.A.). The CRFR2 construct comprised the native 
signal peptide plus receptor sequence and was provided by Dr. Simon Dowell (GSK, 
Stevenage, UK). HA-tagged CLR was as previously described and characterised [9]. Briefly, 
the endogenous signal peptide was replaced by the 21-residue CD8A signal peptide, followed 
by a four-residue linker (DYAS), then the HA-tag plus a further linker (SLGGPSLEGSA), 
with the receptor sequence commencing at E23. FLAG-RAMP2 was as described previously 
[8], with the FLAG-tag inserted after the final residue of the signal peptide.   
 
2.2. Cell culture 
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COS-7 cells, HEK 293T cells and HEK 293S cells (a gift from AstraZeneca), were cultured 
in Dulbecco’s Modified Eagle Medium (DMEM)/F12 supplemented with 10 % heat-
inactivated fetal bovine serum (FBS) plus 1% antibiotic/antimycotic (Sigma) and incubated at 
37 °C in humidified 95 % air and 5 % CO2. Cells were passaged 1 in 5 every 3 days when 
confluency was at ~80 %. HEK 293 cells lacking the calcitonin receptor ([∆CTR]HEK 293 
cells) were a gift from Drs. David Hornigold, Jacqueline Naylor and Alessandra Rossi 
(MedImmune, Cambridge, UK). [∆CTR]HEK 293 cells were cultured in Minimal Essential 
Medium supplemented with 10 % heat-inactivated FBS plus 1 % non-essential amino acids 
and incubated at 37 °C in humidified 95 % air and 5 % CO2 and passaged 1 in 5 every 5 days.  
 
2.3. Flow cytometry  
 
Fluorescence-activated cell sorting (FACS) was used to assess cell-surface expression of 
FLAG-RAMP2. HEK 293S, HEK 293T or [∆CTR]HEK 293 cells were transfected using 
Fugene HD (Promega) in accordance with the manufacturer’s instructions using a 1:3 (w:v) 
DNA:Fugene ratio. COS-7 cells were transfected with PEI, using a 1:3 (w:v) ratio of 
DNA:PEI. Co-transfections utilised 0.25 μg DNA per construct per well, a total of 0.5 μg 
DNA per well. The DNA/PEI mix was diluted in un-supplemented DMEM/F12 to a total 
volume of 25 PL and incubated at room temperature for 10 min before addition to cells 
cultured in complete media. Transfected cell lines were grown for 48 h prior to assaying. 
Mock-transfections were used as control. Transiently transfected cells were removed from the 
plate using trypsin and washed with PBS prior to counting. 5 x 105 cells were washed three 
times in FACS buffer (PBS supplemented with 1 % BSA plus 0.03% sodium azide). Cells 
were then resuspended in 50 μL FACS buffer containing APC-conjugated anti-FLAG 
monoclonal antibody (BioLegend, diluted 1:100 in FACS buffer) and incubated in the dark at 
room temperature for 1 h. The cells received a further three washes in FACS buffer and were 
re-suspended in 50 μL FACS buffer. To account for dead cells, 2.5 μL propidium iodide was 
added to each sample. Samples were analysed using BD Accuri C6 flow cytometer (BD 
Biosciences) with excitation and emission wavelengths of 633 nm and 660 nm, respectively. 
An increase in APC intensity indicated increased plasma membrane expression of FLAG-
RAMP. 
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2.4. Enzyme-linked immunosorbant assay (ELISA) 
 
ELISA was used to assess cell-surface expression of HA-CRFR1Dand HA-CRFR1E HEK 
293S cells were seeded on poly D-lysine-coated 24-well plates at ~1.5 x 105 cells/well, 
transfected with PEI as described previously [8, 9] and incubated for 48 h post-transfection. 
Mock-transfected cells were used as control to determine the background value. ELISA was 
carried out as previously described [8]. The primary antibody (mouse anti-HA, Sigma 
H9658) was diluted 1:3500 in blocking solution and the secondary antibody (horse anti-
mouse HRP-linked IgG, New England Biolabs, 7076S) was diluted 1:3500 in PBS. 
 
2.5. Reverse-transcription-polymerase chain reaction (RT-PCR) 
 
RNA was extracted from COS-7, HEK 293T, HEK 293S or [∆CTR]HEK 293 cells using 
Ambion RNAqueous™-4PCR kit (Life Technologies) as per the manufacturer’s instructions. 
All RNA samples were treated with DNase I to remove any contaminating genomic DNA. 
Reverse transcription was performed using QuantiTect reverse transcription kit (Qiagen) as 
per the manufacturer’s instructions. Minus Reverse Transcriptase negative controls were 
performed simultaneously and the PCR amplification was performed using the following 
conditions: 95 ˚C - 30 sec, 60 ˚C - 30 sec and 68 ˚C – 20 sec for 30 cycles then 68 ˚C – 5 
minutes. Gene-specific primers to all RAMPs and CTR and CLR were used as follows: 
RAMP1, forward (5’-CTGCCAGGAGGCTAACTACG-3’) and reverse (5’-
GACCACGATGAAGGGGTAGA-3’) [10]; RAMP2, forward (5’-
GGGGGACGGTGAAGAACTAT-3’) and reverse (5’- GTTGGCAAAGTGGATCTGGT-3’) 
[10]; RAMP3, forward (5’- AACTTCTCCCGTTGCTGCT-3’) and reverse (5’-
GACGGGTATAACGATCAGCG-3’) [10]; CTR forward (5’-
CCTATCACCCAATAGAGCCCAAG-3’) and reverse (5’-
TGCATTCGGTCATAGCATTTGTA-3’) (PrimerBank ID, 260064026c1); CLR forward (5’- 
ACCAGGCCTTAGTAGCCACA-3’) and reverse (5’- ACAAATTGGGCCATGGATAA-3’) 
[10]; and GAPDH forward (5’-TGCACCACCAACTGCTTAGC-3’) and reverse (5’-
GGCATGGACTGTGGTCATGAG-3’). All products were resolved on a 2 % agarose gel and 
imaged using a G:Box iChemi gel documentation system utilising GeneTools analysis 
software (Syngene) with densitometry performed using GeneTools. Expression of RAMP, 
CLR and CTR was standardised to the expression of the housekeeping gene glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) as described previously [11]. 
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2.6. cAMP accumulation assays 
 
Assays were performed as described previously [9]. Briefly, HEK-293 cells transiently-
transfected with an individual CRFR subtype were washed in PBS, resuspended in PBS 
containing 0.1% BSA plus 0.5 mM IBMX, and seeded at 2000 cells/well in 384-well white 
Optiplates. CRF was added at the concentrations indicated in the range of 1 pM to 1 µM and 
cAMP accumulation was measured after 8 min using a LANCE cAMP detection kit 
(PerkinElmer Life Sciences). Plates were read using a Mithras LB 940 multimode micro-
plate reader (Berthold Technologies). Values were converted to concentration using a cAMP 
standard curve performed in parallel and standardised to cells stimulated with forskolin (100 
µM) which provided the system maximum. 
 
2.7. CRF-induced RAMP2 internalisation 
FACS was used to determine RAMP2 internalisation induced by agonist stimulation of 
CRFR1D and CRFR1E. HEK293S cells were transfected as above. 48 h post-transfection, 
cells were removed from the plate using trypsin and washed with PBS. 5 x 105 cells were 
incubated in PBS supplemented with 0.1 % BSA ± 1 PM CRF for 1 h at room temperature, 
washed with ice-cold FACS buffer and placed on ice. Cells were then assayed as described 
above (Section 2.4) but kept at 4 qC throughout. 
 
 
 
2.8. Molecular modelling 
 
The sequences corresponding to the full length CRFR1 and CRFR2E receptor were obtained 
from UNIPROT [12] and submitted to the SignalP [13] server to determine the position of the 
cleavable signal peptides. A manual sequence alignment was generated between the CRF1R, 
CRF2R, CLR with the signal peptides removed and was used to generate homology models 
using the crystal structures of CLR-RAMP2 (PDB: 4RWF [6]) as templates. MODELLER  
[14] was used to generate 1000 models of each CRFR1:RAMP2 and CRFR2ERAMP2 which 
were subsequently refined and scored using ROSETTA [15]. The best 50 ROSETTA scored 
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structures were clustered and the middle structure from the largest cluster for each model was 
visually examined.  
 
2.9. Data analysis 
 
GraphPad Prism v7.0 was used for data and statistical analysis (GraphPad Software Inc, San 
Diego, CA). Flow cytometry and ELISA data were normalized to cell-surface expression (of 
RAMP or receptor) for cells co-transfected with calcitonin receptor-like receptor (HA-CLR) 
and FLAG-RAMP2 (100 %) and cells transfected with empty vector (0 %). CLR is the 
archetypical partner GPCR for RAMP2. Student’s t-tests were performed on data where there 
was a comparison between the means of two data sets. A one-way ANOVA was performed 
when three or more means were compared, with post-hoc Dunnett’s test or Tukey’s test as 
appropriate. A result was determined to be statistically significant if the P-value was <0.05.  
 
 
3. Results 
 
3.1. The CRFR1α, CRFRβ and CRFR2β constructs are functional 
 
It was important to establish that the  CRFR1α, CRFR1β and CRFR2β constructs used in this 
study were expressed at the cell surface and were functional with respect to mediating CRF-
induced intracellular signaling. Dose-response curves of CRF-stimulated cAMP production 
were generated for each CRFR subtype (Fig. 1). CRF had the expected potency order of 
CRFR1D> CRFR1E>CRFR2β [1]. 
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Fig. 1. CRF-induced cAMP production by individual CRFR subtypes. 
The cAMP dose-response curves were constructed for CRFR1α (z), CRFR1β (■), CRFR2β 
(▲), or vector-only control ({) in response to CRF stimulation at the concentrations 
indicated using transiently-transfected HEK 293T cells. The cAMP values were normalised 
(100%) to the maximal cAMP concentration produced by 100 µM forskolin (range; 66.5 nM-
69.5 nM per 2000 cells). Data are the mean ± s.e.m. of 4-6 independent experiments 
performed in triplicate. 
 
3.2 Co-expression of RAMP2 and CRF receptors in COS-7 cells 
 
CRF receptor (CRFR) subtypes were individually co-expressed with FLAG-tagged RAMP2 
(FLAG-RAMP2) in COS-7 cells. When cell-surface expression of FLAG-RAMP2 was 
determined by flow cytometry, a significant increase was observed in the presence of 
CRFR1D (8.0-fold) or CRFR1E7.5-foldIn marked contrast, CRFR2E co-expression did 
not increase RAMP2 cell-surface expression (Fig. 2). 
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Fig. 2. The effect of co-expression of individual CRFR subtypes on cell-surface expression of 
FLAG-RAMP2 in COS-7 cells. 
Expression was normalised (100%) to that seen when FLAG-RAMP2 was co-expressed with 
CLR, the archetypical GPCR partner for RAMP2. Data are the mean ± s.e.m. of three 
independent experiments performed in triplicate. ***p<0.001, one way ANOVA followed by 
Dunnett’s test. 
 
 
3.3. The effect of cell context on the interaction of CRFR subtypes with RAMP2 
 
It has been reported previously that interaction of CRFR1E with RAMP2 was influenced by 
the cell-line employed, whereby the increase in cell-surface expression of RAMP2 was much 
greater in HEK 293S than CHO-K1 cells [8]. Consequently, the effect of the cell context in 
which the proteins were expressed was also investigated. When HEK 293T cells were 
employed, both of the CRFR1 subtypes increased FLAG-RAMP2 cell-surface expression 
(Fig. 3). This was the same effect observed in COS-7 cells (Fig. 2), however the extent of the 
increase in HEK 293T cells, for both CRFR1D (3.4-fold) and CRFR1E 4.6-foldwas 
smaller than that observed in COS-7 cells.  As with COS-7 cells, there was no change in the 
cell-surface expression of FLAG-RAMP2 following co-expression with CRFR2Ein 
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+(.7cells (Fig. 3). A very similar effect was also observed using HEK 293S cells. 
There was a significantly increased cell-surface expression of FLAG-RAMP2 in the presence 
of CRFR1D (2.8-fold) or CRFR1E (3.4-fold) in HEK 293S cells but such an increase was 
completely absent in the presence of the CRFR2E(Fig. 4a).  
 
   
 
Fig. 3. The effect of co-expression of individual CRFR subtypes on cell-surface expression of 
FLAG-RAMP2 in HEK 293T cells. 
Expression was normalised (100%) to that seen when FLAG-RAMP2 was co-expressed with 
CLR, the archetypical GPCR partner for RAMP2. Data are mean ± s.e.m. of three 
independent experiments performed in triplicate. ***p<0.001, one way ANOVA followed by 
Dunnett’s test. 
 
 
Wootten and co-workers [8] reported a reciprocal interaction between RAMP2 and 
CRFR1Ein HEK 293S cells, whereby the receptor increased RAMP2 delivery to the cell 
surface and likewise, RAMP2 increased cell-surface expression of CRFR1EConsequently, 
the ability of RAMP2 to traffic HA-CRFR1D and HA-CRFR1E to the cell surface was 
investigated in this cell line (Fig. 4b). Data presented in Fig. 4b establish that RAMP2 co-
expression enhanced the delivery of both HA-CRFR1D (38.6%) and HA-CRFR1E (29.2%) to 
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the cell surface. The increase in HA-CRFR1Ecell-surface expression observed in this study 
was consistent with the effect reported previously [8]. 
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Fig. 4. Cell-surface expression of CRFR1 subtypes and RAMP2 in HEK 293S cells.  
Panel a; The effect of co-expression of individual CRFR subtypes on cell-surface expression 
of FLAG-RAMP2. Panel b; The effect of RAMP2 co-expression on the cell-surface 
expression of HA-CRFR1D and HA-CRFR1E. Expression was normalised (100%) to that 
seen when FLAG-RAMP2 was co-expressed with HA-CLR, the archetypical GPCR partner 
for RAMP2. Data are the mean ± s.e.m of n>3 independent experiments performed in 
triplicate. *p<0.05, ** p< 0.01, ***p<0.001, one way ANOVA followed by Dunnett’s test 
(panel a) or Tukey’s test (panel b).  
 
 
 
3.4. Co-expression of RAMP2 and CRFR subtypes in ['CTR]HEK 293 cells 
 
It is well-established that the calcitonin receptor (CTR) can interact with all three RAMPs [7] 
and that HEK 293 cells usually express the CTR endogenously. It was therefore possible that 
endogenous CTR expression could influence RAMP2 interaction with co-transfected CRFRs 
by providing an alternative partner for RAMP2. This was investigated using a HEK 293 cell 
line completely lacking endogenous CTR (['CTR]HEK 293 cells). RAMP2 delivery to the 
cell surface was markedly increased when co-transfected with CRFR1D (18.4-fold) or 
CRFR1E (14.6-fold). This was the largest increase in RAMP2 cell-surface expression 
observed with any cell line employed in this study. In marked contrast, but consistent with all 
the other cell lines tested, there was no increase in RAMP2 expression with CRFR2E (Fig. 5). 
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Fig. 5. The effect of co-expression of individual CRFR subtypes on cell-surface expression of 
FLAG-RAMP2 in ['CTR]HEK 293 cells. 
Expression was normalised (100%) to that seen when FLAG-RAMP2 was co-expressed with 
CLR, the archetypical GPCR partner for RAMP2. Data are the mean ± s.e.m of three 
independent experiments performed in triplicate. ***p<0.001, one way ANOVA followed by 
Dunnett’s test.  
 
3.5. Endogenous expression of RAMPs and receptors in the cell lines employed in this 
study 
 
The mRNA expression levels of all three RAMPs, relative to the housekeeping gene 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), was determined in all the cell lines 
(COS-7, HEK 293T, HEK 293S and ['CTR]HEK 293). mRNA expression was also 
determined for two GPCRs (CTR and CLR) that are well-established partner receptors for 
RAMPs (Fig. 6).  In COS-7 cells, the RAMPs and the two GPCRs were either absent or 
detected at only very low levels. In contrast, there was appreciable expression of RAMP1, 
RAMP2 and CLR in both HEK 293T and HEK 293S cells. The low level expression of CTR 
detected in the HEK 293T/S cells was ablated in the ['CTR]HEK 293 cells as expected. In 
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addition, the ['CTR]HEK 293 cells exhibited very low levels of expression of each RAMP 
and CLR (Fig. 6). 
 
 
 
Fig. 6. Expression of mRNA for RAMPs, CTR and CLR.  
Expression was measured by RT-PCR in the cell lines indicated and standardised to GAPDH. 
Data are mean ± s.e.m (n = 3).  
 
3.6. Internalisation of RAMP2 following agonist challenge of co-transfected CRFR 
It is well-established that agonist stimulation causes internalisation of GPCRs. To investigate 
whether there was likely to be a physical interaction between RAMP2 and the CRFR1 
subtypes, it was determined whether CRF-stimulation of the CRFR1D or CRFR1E isoforms 
caused a decrease in cell-surface expression of FLAG-tagged RAMP2. As can be seen in Fig 
7, following CRF challenge (1 PM for 1 h), a reduction in RAMP2 on the cell-surface was 
observed with both receptors. 
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Fig 7.  The effect of CRF stimulation of the a) CRFR1D and b) CRFR1E subtypes on cell-
surface expression of FLAG-RAMP2 in HEK293S cells. 
CRF treatment was for 1h. Expression was normalised (100%) to that seen when FLAG-
RAMP2 was co-expressed with CLR. Data are the mean ± s.e.m. of three or four independent 
experiments. *p<0.01, one way ANOVA followed by Dunnett’s test.  
 
 
3.7. Molecular modelling of CRFR:RAMP2 complexes 
 
Computational molecular modelling can provide insights into the molecular mechanisms 
underpinning empirical observations. From data presented above, it is clear that the CRFR1 
variants exhibit interaction with RAMP2 whereas in marked contrast the CRFR2 does not. 
This subtype-specific difference was observed in all the cell lines utilised. In order to 
investigate why the CRFR1 splice variants might be better able to form a heterodimer with 
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RAMP2 compared to CRFR2Ehomology models of the ectodomains of CRFR1:RAMP2 
and CRFR2E:RAMP2 were constructed based on the crystal structure of the CLR:RAMP2 
ectodomain complex (3AQF; Kusano et al., 2011) and are directly compared in Fig. 8. 
Assuming a direct CRFR:RAMP2 interaction and that the complexes have a similar 
GPCR:RAMP interface to that seen in CLR:RAMP2, then residues Q26, D27, E31 and S35 
of CRFR1 pack against RAMP2 (Fig. 8). Interestingly, this constitutes a smaller interface 
than seen with CLR where I41, M42, N45, Y46, Y49 and I52 all contribute to the association 
[6, 16]. With reference to Fig. 8, the two negatively-charged residues D27 and E31 of CRFR1 
are positioned close to a histidine (H124) of RAMP2. However, in CRFR2E, the residue 
corresponding to E31 is replaced by a histidine (H52), which will undergo electrostatic 
repulsion away from H124 of RAMP2. Consequently, in CRFR2E, H52 moves away from 
the RAMP2 interface as does E48, the equivalent of D27 in CRFR1. There are also 
differences in loop 2 of the ECDs of the receptors, at the tip of the sheet formed by the E1 
and E2 strands of these domains. In CRFR1receptors, this is close to RAMP2, allowing I51 
of CRFR1 to pack against the RAMP. In contrast, the equivalent loop region of CRFR2E is 
bent away from RAMP2 so that I74 (the equivalent of I51 in CRFR1) fails to make contact 
with the RAMP (Fig. 8). 
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Fig. 8. Molecular models of a) CRFR1:RAMP2 and CRFR2E:RAMP and b) CLR:RAMP2 
Molecular models of CRFR1ERAMP2 and CRFR2ERAMP2 are shown superimposed, with 
CRFR1E (yellow), CRFR2E (green) and RAMP2 (blue). Individual key residues in the 
heterodimer interface, which are referred to in the text, are indicated for each CRFR subtype. 
CLR:RAMP2 is from PDB 3N7S [6] 
 
 
 
 
4. Discussion 
 
RAMPs have been shown to interact with a wide range of family B GPCRs and thereby affect 
fundamental characteristics of these receptors. These RAMP-mediated effects include 
alteration of cell-surface expression and changes to the receptor’s ligand binding profile and 
intracellular signaling [4]. The best-characterized of these RAMP-mediated effects are with 
the receptors CLR and CTR [7]. The widespread occurrence of RAMP:GPCR interactions 
was evident following characterisation of a RAMP2+/- knockdown mouse strain, which 
revealed a broad spectrum of physiological changes, consistent with RAMP2 modulating an 
extensive and diverse range of receptors [17].  
 
CRF stimulation of ACTH release from the pituitary gland is of pivotal importance to the 
physiological role of this hormone [3]. It is noteworthy therefore, that the RAMP2+/- mouse 
line exhibited a decrease (~20%) in CRF-stimulated release of ACTH into the blood 
compared to wild-type mice [8], thereby establishing the importance of RAMP2:CRFR 
interaction in vivo. Furthermore, the results with the RAMP2+/- mouse line probably under-
represent the importance of RAMP2 to CRF function, as the mice are only heterozygote for 
RAMP2 and not a complete RAMP2 knockout strain (RAMP2-/- is lethal in embryo). The 
current study investigated the ability of RAMP2 to interact with human CRFR subtypes by 
measuring changes in FLAG-tagged RAMP2 cell-surface expression induced by co-
expression of the individual CRF receptor subtypes CRFR1DCRFR1E and CRFR2E Both 
of the CRFR1 isoforms were shown to  enhance delivery of RAMP2 to the cell surface. Our 
data for CRFR1E are in agreement with the findings of Wootten et al. [8] and furthermore, 
establish that RAMP2 interaction extends to the predominant CRFR1D isoform. Thus, RAMP 
modulation of either CRFR1 subtype should be considered in cells where these receptors can 
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be shown to be co-expressed with RAMP2. As the effects of RAMPs on GPCRs can be 
affected by the cell line, four different cell-lines were utilised to investigate the effect of 
varying cellular context viz. COS-7, HEK 293T, HEK 293S, plus ['CTR]HEK 293 (a HEK 
293 cell-line lacking endogenous calcitonin receptor). In each case, the magnitude of the 
enhancement of RAMP2 cell-surface expression was similar for both CRFR1 isoforms, 
although the fold-increase varied between cell lines (['CTR]HEK 293>COS-7>HEK 
293T>HEK 293S). In addition, interaction of RAMP2 with either CRFR1Dor CRFR1E 
resulted in an increase in the delivery of both the RAMP and the receptor to the cell surface. 
CRFR1Dand CRFR1E share identical sequences, except for a 29-residue deletion in ICL1 of 
CRFR1D. It seems unlikely that ICL1 is in direct contact with the RAMP [5]. 
 
The largest enhancement of RAMP2 cell-surface expression was observed in ['CTR]HEK 
293 cells which lack endogenous CTR (Fig. 5). This increase in RAMP2 delivery to the cell 
surface was notably higher in ['CTR]HEK 293 cells than that observed in HEK 293S cells 
(6.6-fold greater and 4.2-fold greater for CRFR1D and CRFR1E respectively). Whilst the 
CTR can complex with RAMP2 (and so could act as a sink for RAMP2 in competition with 
the CRFR1 isoforms), this interaction has been reported to be weak [18]. Therefore it is not 
clear if the absence of CTR alone is sufficient to explain the increase in RAMP2 cell-surface 
abundance generated by CRFR1 isoforms in ['CTR]HEK 293 cells compared to HEK 293S 
cells. There may be other RAMP-interacting proteins differentially expressed by the cells, to 
dilute the RAMP pool. However, based on mRNA data presented in Fig. 6, there was a 
negative correlation between endogenous expression levels of RAMP2 in HEK-based cell 
lines and the extent to which FLAG-RAMP2 trafficking was affected by either CRFR1D or 
CRFRE. This suggests that endogenous, untagged RAMPs may interact with the CRFR1, in 
effect competing with the transfected FLAG-RAMPs, thus diluting the cell-surface 
expression of FLAG-RAMPs. This reasoning indicates that receptor:RAMP stoichiometry is 
an important consideration but it is very rare for RAMP and receptor expression to be 
quantified in a single cell type [19]; we are unaware of any study where this has been done 
for every potential RAMP-interacting GPCR. Indications are that individual RAMPs and 
GPCRs are expressed at broadly similar levels [20], as seen in this study (Fig 6) but more 
work is needed to understand their interactions at a cellular level. 
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Throughout this work, the assumption has been that there is a physical association between 
RAMP2 and the CRF receptors. We cannot rule out an indirect effect of the RAMP on the 
receptor. However, robust physical interactions are seen with CLR and RAMPs [5, 6] and the 
simplest interpretation of the ability of prolonged CRF treatment to reduce cell surface 
RAMP2 expression (Fig 7) is that there is internalisation of a CRFR1-RAMP2 heterodimer. 
Furthermore, the effects of RAMP modulation on CRFR1E pharmacology [8] (also seen with 
the RAMP2 interaction with the glucagon receptor [21]), suggest that a physical interaction 
between the receptor and the RAMP is the most plausible mechanism. This may also provide 
a further explanation of cell line variability, if there are different degrees of 
compartmentalisation between RAMPs and GPCRs. 
 
In marked contrast to the CRFR1 isoforms, there was no evidence that RAMP2 cell-surface 
expression was affected by CRFR2E in any of the cell lines employed, Thus if CRFR:RAMP 
heterodimerisation is the basis for this effect, it would seem that the CRFR2E does not form 
dimers with RAMP2. The CRFR2E shares ~70% amino acid sequence identity with CRFR1, 
with most of the divergence in sequence occurring in the ECD. Insights from computational 
molecular modelling suggested a feasible mechanism, arising from differences in the ECDs, 
to explain the subtype-specific interaction observed between CRFRs and RAMP2. These 
modelling studies indicated that there are charge differences between the residues of CRFR1 
and CRFR2E that pack against a histidine (H124) of RAMP2, located in the GPCR:RAMP 
interface. Whilst CRFR1 isoforms form a favourable interaction via E31, electrostatic 
repulsion of the corresponding CRFR2E residue (H52) would result in failure of CRFR2E to 
complex with RAMP2. In addition, the smaller and more polar contact interface between 
CRFR1:RAMP2 compared to CLR:RAMP2 might explain why formation of CLR:RAMP2 
complexes is more robust than CRFR1:RAMP2 complexes. We cannot exclude that 
differences in the transmembrane domains of the receptors may also be important. 
 
In conclusion, the study demonstrates that both CRFR1D and CRFR1E can interact with 
RAMP2 but the magnitude of the effect was cell line-dependent. In contrast, the 
CRFR2Esubtype did not complex with RAMP2 in any cell line examined. Molecular 
modelling studies suggested that this difference between CRFR1 and CRFR2 may be due to 
subtype-specific differences in individual residues in the ECDs which contributed to the 
CRFR contact interface in a RAMP2:CRFR complex. 
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